Status:
COMPLETED
Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Osteoarticular Infection
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.
Eligibility Criteria
Inclusion
- Patient over 18 years
- Inpatient orthopedic surgery
- Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
- Bacteria resistant to lincosamides, quinolones and rifampicin
- Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
- Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)
Exclusion
- Patient not affiliated to the social security
- Pregnant and lactating women
- Known hypersensitivity to teicoplanin (rash, ...)
- Patients with a central catheter or an implantable chamber
- Patient hemodialysis
- Patient has another participant biomedical research on a drug to prevent drug interactions
- Patient minor
- Patient major protected (protection of the court, wardship, trusteeship)
- Patient admitted for emergency or incapable of consent
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01815541
Start Date
March 1 2013
End Date
July 1 2015
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, Picardie, France, 80054